anabol dianabol methandrostenolone/ methandienone
Following oral torasemide anabol dianabol methandrostenolone/ methandienone rapidly and almost completely absorbed in the gastrointestinal tract. Torasemide maximum plasma concentration observed after 1-2 hours after administration. Bioavailability is approximately 80-91% and more edema. Contact with blood plasma proteins – 99%. The volume of distribution is 16 liters. It is metabolized in the liver by cytochrome system . The of torasemide and its metabolites anastrozole bodybuilding in healthy volunteers is 3-4 hours. Torasemide total clearance of 40 ml / min and renal clearance.
- Edema caused by congestive heart failure, liver disease, kidney and lung.
- Primary hypertension (used alone or in combination with other antihypertensive agents).
Contraindications: Hypersensitivity to torasemide, and sulfonamides; anuria; hepatic coma and prekomatosnoe condition, chronic renal failure with progressive azotemia, arrhythmia, hypotension, pregnancy, lactation (no data on the use during lactation), age 18 years (effectiveness and safety not installed).
Precautions: diabetes mellitus, gout, disorders of water and electrolyte balance, impaired liver function, cirrhosis, predisposed to hyperuricemia.
Dosage and administration . Inside Adults: Oedema: 5 mg 1 time per day. If necessary, the dose can be gradually increased to 1 20 mg once a day. In some cases it is recommended to anabol dianabol methandrostenolone/ methandienone per day. Congestive heart failure: 5 – 20 mg 1 time per day. If necessary, the daily dose can be gradually increased (doubling it), to a maximum of 200 mg. Chronic renal failure: The initial dose is 20 mg per day. If necessary, this dose can be gradually increased (doubling it), before reaching the diuretic effect clinical equipoise definition. The maximum daily dose – 200 mg. Cirrhosis: 5 – 10 mg 1 time per day. If necessary, the dose can be gradually increased (doubling it), to achieve an appropriate diuretic effect. There has been no properly controlled studies in patients with liver disease with doses of 40 mg per day. Primary hypertension: 2.5 mg orally 1 time day. If necessary, the dose can be gradually increased up to 5 mg per day. According to studies, a dose in excess of 5 mg per day did not lead to further decrease blood pressure. The maximum effect is achieved after about twelve weeks of continuous treatment. Elderly patients: Elderly patients do not require a special adaptation of the dose. Children: There are no data regarding the use o in children.
Food does not affect the absorption , so the drug can be taken regardless of meals.
Side effects: From the side of blood: in some cases, may experience changes in blood biochemical parameters: reduction in the number of red blood cells and white blood cells and platelets, hypovolemia, electrolyte imbalance, hypokalemia, increased uric acid in the blood serum glucose and lipids. Increased levels of certain liver enzymes, eg gamma-GT. With the cardiovascular system: in some cases, due to the thickening of the blood, having blood circulation disorders and thromboembolism, lowering blood pressure of blood. On the part of the digestive tract: the various dysfunctions of gastrointestinal -kishechnogo tract phenyl propanoate, loss of appetite, and in some cases may develop pancreatitis. On the part of the kidney and urinary tract infections: acute urinary retention, increased levels of urea and creatinine in plasma. On the part of the central nervous system: headache, dizziness, weakness, drowsiness , confusion, seizures and limb paresthesia. Allergic reactions: itching, rash and photosensitivity. From the senses: visual disturbances, tinnitus, deafness. Other: dry mouth.
Overdose symptoms – typical picture of poisoning do not. In case of overdose – forced urination, accompanied by hypovolemia, electrolyte imbalance, followed by a fall in blood pressure, drowsiness, confusion, collapse. Gastrointestinal disorders may be observed. A anabol dianabol methandrostenolone/ methandienones pecific antidote androgel coupon is not known. Symptomatic treatment involves the reduction of the dose or stop the drug and at the same time replenishing the loss of fluids and electrolytes.